ICU MED INC's ticker is ICUI and the CUSIP is 44930G107. A total of 277 filers reported holding ICU MED INC in Q3 2020. The put-call ratio across all filers is 0.22 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,707,000 | -34.7% | 39,554 | -2.2% | 0.02% | -27.6% |
| Q2 2023 | $7,208,000 | +5.7% | 40,449 | -2.1% | 0.03% | +3.6% |
| Q1 2023 | $6,817,000 | +4.0% | 41,328 | -0.7% | 0.03% | 0.0% |
| Q4 2022 | $6,554,000 | -4.7% | 41,620 | -8.8% | 0.03% | -9.7% |
| Q3 2022 | $6,875,000 | -8.1% | 45,649 | +0.3% | 0.03% | -3.1% |
| Q2 2022 | $7,484,000 | -26.6% | 45,528 | -0.6% | 0.03% | -11.1% |
| Q1 2022 | $10,202,000 | -6.9% | 45,825 | -0.7% | 0.04% | -2.7% |
| Q4 2021 | $10,955,000 | +0.9% | 46,159 | -0.8% | 0.04% | -5.1% |
| Q3 2021 | $10,859,000 | +27.2% | 46,531 | +12.2% | 0.04% | +30.0% |
| Q2 2021 | $8,536,000 | +2.9% | 41,478 | +2.7% | 0.03% | -9.1% |
| Q1 2021 | $8,294,000 | +4.1% | 40,370 | +8.7% | 0.03% | -8.3% |
| Q4 2020 | $7,965,000 | +23.8% | 37,135 | +5.5% | 0.04% | +2.9% |
| Q3 2020 | $6,432,000 | -10.2% | 35,196 | -9.4% | 0.04% | -14.6% |
| Q2 2020 | $7,162,000 | +36.6% | 38,859 | +49.5% | 0.04% | +13.9% |
| Q1 2020 | $5,243,000 | +19.9% | 25,987 | +11.2% | 0.04% | +56.5% |
| Q4 2019 | $4,374,000 | +25.0% | 23,375 | +6.7% | 0.02% | +21.1% |
| Q3 2019 | $3,498,000 | -27.2% | 21,915 | +14.9% | 0.02% | -26.9% |
| Q2 2019 | $4,803,000 | -24.1% | 19,065 | -27.8% | 0.03% | -21.2% |
| Q1 2019 | $6,324,000 | +2.3% | 26,423 | -1.9% | 0.03% | -8.3% |
| Q4 2018 | $6,184,000 | -33.3% | 26,929 | -17.9% | 0.04% | -21.7% |
| Q3 2018 | $9,273,000 | +22.1% | 32,797 | +26.8% | 0.05% | +21.1% |
| Q2 2018 | $7,595,000 | +54.1% | 25,863 | +32.4% | 0.04% | +46.2% |
| Q1 2018 | $4,930,000 | +15.5% | 19,531 | -1.2% | 0.03% | +23.8% |
| Q4 2017 | $4,270,000 | +16.2% | 19,770 | 0.0% | 0.02% | +10.5% |
| Q3 2017 | $3,674,000 | -50.7% | 19,770 | -54.2% | 0.02% | -5.0% |
| Q2 2017 | $7,452,000 | +94.0% | 43,198 | +71.7% | 0.02% | -9.1% |
| Q1 2017 | $3,841,000 | +1.0% | 25,153 | 0.0% | 0.02% | +4.8% |
| Q4 2016 | $3,803,000 | +154.6% | 25,153 | +112.8% | 0.02% | +133.3% |
| Q3 2016 | $1,494,000 | – | 11,818 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EVR Research LP | 22,000 | $4,719,000 | 3.86% |
| NUANCE INVESTMENTS, LLC | 901,483 | $193,359,000 | 3.73% |
| Nitorum Capital, L.P. | 417,241 | $89,494,000 | 3.46% |
| Tamarack Advisers, LP | 73,000 | $15,452,000 | 3.22% |
| PFM Health Sciences, LP | 267,817 | $57,444,000 | 2.02% |
| KIRR MARBACH & CO LLC /IN/ | 22,222 | $4,766,000 | 1.49% |
| PURA VIDA INVESTMENTS, LLC | 174,399 | $37,407,000 | 1.36% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,584 | $554,000 | 0.88% |
| Findlay Park Partners LLP | 528,825 | $113,428,000 | 0.79% |
| Altium Capital Management LP | 9,321 | $1,999,000 | 0.75% |